|
Synonyms: Example 10 [WO2014071832] | SAF-189 | SAF-189s
Compound class:
Synthetic organic
Comment: Rufutalkib is the INN for an anaplastic lymphoma kinase (ALK) inhibitor, that was included in WHO INN Proposed List 135 (July 2026). There is a structure match for a compound claimed in patent WO2014071832A1 [2]. Online resources suggest that Fochon Pharmaceutical's lead ALK and ROS proto-oncogene 1 (ROS1) kinase inhibitor SAF-189 is also named foritinib, however this is not a bona fide INN. It is likely that rufutalkib is the proposed INN for SAF-189. SAF-189 is intended as an orally bioavailable anti-tumour agent wit potential to overcome crizotinib resistance [1].
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| SAF-189/foritinib was progressed as a clinical candidate, for the treatment of ALK-rearranged or ROS1-mutated advanced non-small cell lung cancers. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06569420 | Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC | Phase 3 Interventional | Fosunpharma | ||